SWTX logo

SpringWorks Therapeutics (SWTX) EBITDA

annual EBITDA:

-$274.66M+$66.68M(+19.54%)
December 31, 2024

Summary

  • As of today (June 18, 2025), SWTX annual EBITDA is -$274.66 million, with the most recent change of +$66.68 million (+19.54%) on December 31, 2024.
  • During the last 3 years, SWTX annual EBITDA has fallen by -$101.69 million (-58.78%).
  • SWTX annual EBITDA is now -1386.75% below its all-time high of -$18.47 million, reached on December 31, 2018.

Performance

SWTX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSWTXincome statement metrics

quarterly EBITDA:

-$81.09M-$763.00K(-0.95%)
March 31, 2025

Summary

  • As of today (June 18, 2025), SWTX quarterly EBITDA is -$81.09 million, with the most recent change of -$763.00 thousand (-0.95%) on March 31, 2025.
  • Over the past year, SWTX quarterly EBITDA has increased by +$12.11 million (+13.00%).
  • SWTX quarterly EBITDA is now -815.76% below its all-time high of $11.33 million, reached on December 31, 2020.

Performance

SWTX quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSWTXincome statement metrics

TTM EBITDA:

-$262.55M+$12.11M(+4.41%)
March 31, 2025

Summary

  • As of today (June 18, 2025), SWTX TTM EBITDA is -$262.55 million, with the most recent change of +$12.11 million (+4.41%) on March 31, 2025.
  • Over the past year, SWTX TTM EBITDA has increased by +$94.55 million (+26.48%).
  • SWTX TTM EBITDA is now -4922.94% below its all-time high of -$5.23 million, reached on September 30, 2018.

Performance

SWTX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSWTXincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

SWTX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+19.5%+13.0%+26.5%
3 y3 years-58.8%-32.1%-28.3%
5 y5 years-365.2%-404.9%-313.9%

SWTX EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-58.8%+19.5%-84.0%+17.2%-28.3%+26.5%
5 y5-year-497.4%+19.5%-815.8%+17.2%-471.1%+26.5%
alltimeall time-1386.8%+19.5%-815.8%+17.2%-4922.9%+26.5%

SWTX EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
-$81.09M(+0.9%)
-$262.55M(-4.4%)
Dec 2024
-$274.66M(-19.5%)
-$80.33M(+40.8%)
-$274.66M(-6.0%)
Sep 2024
-
-$57.06M(+29.5%)
-$292.26M(-8.3%)
Jun 2024
-
-$44.08M(-52.7%)
-$318.71M(-10.8%)
Mar 2024
-
-$93.20M(-4.8%)
-$357.10M(+4.6%)
Dec 2023
-$341.35M(+21.9%)
-$97.92M(+17.3%)
-$341.35M(+6.1%)
Sep 2023
-
-$83.50M(+1.3%)
-$321.62M(+3.9%)
Jun 2023
-
-$82.47M(+6.5%)
-$309.64M(+4.6%)
Mar 2023
-
-$77.45M(-1.0%)
-$295.99M(+5.7%)
Dec 2022
-$279.91M(+61.8%)
-$78.20M(+9.3%)
-$279.91M(+8.8%)
Sep 2022
-
-$71.53M(+3.9%)
-$257.36M(+13.6%)
Jun 2022
-
-$68.82M(+12.2%)
-$226.61M(+10.7%)
Mar 2022
-
-$61.36M(+10.3%)
-$204.69M(+18.3%)
DateAnnualQuarterlyTTM
Dec 2021
-$172.98M(+276.2%)
-$55.65M(+36.5%)
-$172.98M(+63.2%)
Sep 2021
-
-$40.78M(-13.1%)
-$106.00M(+22.2%)
Jun 2021
-
-$46.91M(+58.2%)
-$86.72M(+45.6%)
Mar 2021
-
-$29.65M(-361.7%)
-$59.56M(+29.6%)
Dec 2020
-$45.98M(-22.1%)
$11.33M(-152.7%)
-$45.98M(-38.4%)
Sep 2020
-
-$21.50M(+8.9%)
-$74.61M(+9.1%)
Jun 2020
-
-$19.75M(+23.0%)
-$68.38M(+7.8%)
Mar 2020
-
-$16.06M(-7.2%)
-$63.44M(+7.4%)
Dec 2019
-$59.05M(+219.6%)
-$17.31M(+13.4%)
-$59.05M(+22.6%)
Sep 2019
-
-$15.27M(+3.1%)
-$48.18M(+26.3%)
Jun 2019
-
-$14.81M(+26.9%)
-$38.14M(+63.5%)
Mar 2019
-
-$11.67M(+81.2%)
-$23.33M(+100.0%)
Dec 2018
-$18.47M
-$6.44M(+23.2%)
-$11.67M(+123.2%)
Sep 2018
-
-$5.23M
-$5.23M

FAQ

  • What is SpringWorks Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for SpringWorks Therapeutics?
  • What is SpringWorks Therapeutics annual EBITDA year-on-year change?
  • What is SpringWorks Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for SpringWorks Therapeutics?
  • What is SpringWorks Therapeutics quarterly EBITDA year-on-year change?
  • What is SpringWorks Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for SpringWorks Therapeutics?
  • What is SpringWorks Therapeutics TTM EBITDA year-on-year change?

What is SpringWorks Therapeutics annual EBITDA?

The current annual EBITDA of SWTX is -$274.66M

What is the all time high annual EBITDA for SpringWorks Therapeutics?

SpringWorks Therapeutics all-time high annual EBITDA is -$18.47M

What is SpringWorks Therapeutics annual EBITDA year-on-year change?

Over the past year, SWTX annual EBITDA has changed by +$66.68M (+19.54%)

What is SpringWorks Therapeutics quarterly EBITDA?

The current quarterly EBITDA of SWTX is -$81.09M

What is the all time high quarterly EBITDA for SpringWorks Therapeutics?

SpringWorks Therapeutics all-time high quarterly EBITDA is $11.33M

What is SpringWorks Therapeutics quarterly EBITDA year-on-year change?

Over the past year, SWTX quarterly EBITDA has changed by +$12.11M (+13.00%)

What is SpringWorks Therapeutics TTM EBITDA?

The current TTM EBITDA of SWTX is -$262.55M

What is the all time high TTM EBITDA for SpringWorks Therapeutics?

SpringWorks Therapeutics all-time high TTM EBITDA is -$5.23M

What is SpringWorks Therapeutics TTM EBITDA year-on-year change?

Over the past year, SWTX TTM EBITDA has changed by +$94.55M (+26.48%)
On this page